The Effect of Albumin Value, HALP Score and LCR Value on Predicting Survival and Recurrence in Patients with Pancreatic Adenocancer

Aim The aim of this study is to investigate whether the albumin value and the ratios of biochemical markers; hemoglobin, albumin, lymphocyte and platelet (HALP score) and lymphocyte-C-reactive protein ratio (LCR) can predict the survival and recurrence of the disease in patients with pancreatic adenocarcinoma. Materials and Methods Patients operated for pancreatic adenocarcinoma (n:87) who did not receive neoadjuvant treatment in our clinic between January 2017 and December 2021 were included in the study. The preoperative albumin levels, HALP scores and LCR values were calculated, and analyzed to determine whether the differences in these ratios could predict pathological findings in the early period. Results The average age of 87 patients included in our study was 64.8 ± 9.6 years. 59 (67.8%) of the patients were male and 28 (32.2%) were female. The cut-off value for HALP score was determined as 34.4, the cut-off value for LCR value was 0.61, and the cut-off value for albumin value was 38.55. It was found that the overall survival time of patients with low HALP scores was significantly shorter than patients with high HALP scores (15.8 vs. 19.3 months) (p < 0.01). The overall survival time of patients with low LCR was significantly longer (17.8 vs 18.5 months) than patients with high LCR score (p < 0.01). The overall survival time of patients with high albumin values was found to be significantly longer (14.6 vs 16.3 months) than patients with low albumin values (p < 0.01). Conclusion Low HALP levels and low albumin values were confirmed to be significant independent prognostic factors for disease-free survival and overall survival in pancreatic adenocarcinoma patients.